Advertisement
Dr. Adjei joins Ventaira with more than 20 years of experience in researchand development in the pharmaceutical industry. Most recently, he served asthe Vice President of Research and Development with KOS Pharmaceuticals wherehe was responsible for formulation development and device support for thecompany's inhaled asthma and diabetes franchises. In this role, Dr. Adjei ledthe creation and approval of 32 USPTO aerosol formulation and devicetechnologies, and developed best standards to guide systemic aerosolformulation development of protein drugs. Prior to KOS, Dr. Adjei spent timeat Abbott Laboratories where he directed the development and commercialmanufacture of Lupron Mist(R), the first injectable peptide filed as anoninvasive aerosol. Dr. Adjei is the co-author of the book, InhalationDelivery of Therapeutic Peptides and Proteins, and he is a member of theInternational Symposium on Aerosols in Medicine, the American Association ofPharmaceutical Sciences and the AAPS Aerosol Program Committee, PharmaceuticalTechnology Section. He received a Ph.D. and an M.S. in pharmaceutical scienceand a B.S. in pharmacy from The University of Texas at Austin.
Advertisement
"Dr. Adjei's experience with reformulation of proteins and peptides forpulmonary delivery will be instrumental as we continue to explore delivery ofthese types of molecules with our commercial inhaler," stated Leslie Williams,President and CEO of Ventaira Pharmaceuticals. "Dr. Adjei, along with theother members of our product development team, will be instrumental in movingour clinical program forward and identifying additional products to meet theunmet needs of patients in the rapidly expanding inhalation market."
About Ventaira Pharmaceuticals
Ventaira is a specialty pharmaceutical company that uses its proprietarypulmonary drug delivery technology, Mystic(TM) ((Electrohydrodynamic EHD), andformulation capabilities to deliver respiratory and systemically active drugsmore efficiently and effectively. Ventaira is currently developing its ownproprietary drugs for the treatment of a wide variety of conditions and alsolooks to create opportunities for existing drugs that may be more easilydelivered via inhalation. Ventaira has an exclusive license on a portfolio ofpatents for its Mystic technology.
SOURCE Ventaira Pharmaceuticals, Inc.
